The Indian Supreme Court's ruling against Novartis' attempt to patent cancer drug Gleevec could give poor patients access to affordable drugs while providing an incentive for real innovation, according to this editorial. The ruling will not affect the price of the drug in the U.S. but will authorize the sale of lower-cost generic versions in India and other nations where it doesn't have patent protection. The ruling does not limit all patents for incremental innovation but does encourage drugmakers to demonstrate real improvements in efficacy.

Related Summaries